AIA Group Ltd Purchases 10,378 Shares of Illumina, Inc. (NASDAQ:ILMN)

AIA Group Ltd boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 67.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,829 shares of the life sciences company’s stock after buying an additional 10,378 shares during the period. AIA Group Ltd’s holdings in Illumina were worth $3,596,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC lifted its stake in shares of Illumina by 312.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after acquiring an additional 1,525 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Illumina by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after acquiring an additional 7,114 shares during the last quarter. Dakota Wealth Management lifted its stake in shares of Illumina by 13.8% during the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Illumina by 16.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock worth $281,000 after acquiring an additional 116 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in Illumina by 10.2% during the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock worth $17,108,000 after purchasing an additional 4,548 shares during the period. 89.42% of the stock is owned by institutional investors.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is owned by company insiders.

Illumina Price Performance

Shares of Illumina stock traded down $1.25 on Thursday, hitting $117.04. The company’s stock had a trading volume of 1,217,288 shares, compared to its average volume of 1,754,616. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $232.23. The firm has a fifty day moving average price of $134.31 and a 200-day moving average price of $128.15. The company has a market capitalization of $18.64 billion, a price-to-earnings ratio of -16.12 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the business earned $0.14 EPS. Illumina’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, April 10th. Royal Bank of Canada restated an “outperform” rating and set a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Barclays lifted their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.